Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset
Launched by GILLES BOIRE · Aug 6, 2007
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to better predict the progression of early inflammatory arthritis, particularly rheumatoid arthritis (RA), which affects about 1% of people in Canada. Researchers want to find out if testing for specific antibodies related to RA, along with other severity markers, can help identify which patients are likely to have a more severe form of the disease. By understanding who may need more aggressive treatment early on, doctors can make better decisions to improve patient outcomes and reduce long-term disability.
To participate in this study, individuals should have early rheumatoid arthritis or early inflammatory arthritis. However, those who cannot consent, or have infections or certain types of arthritis that are not being studied, will not be eligible. Participants can expect to undergo specific tests to help determine their prognosis. This research is important, as it may lead to improved treatment strategies and help researchers better group patients in future studies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Early Rheumatoid arthritis
- • Early Inflammatory Arthritis
- Exclusion Criteria:
- • Refusal or inability to consent
- • Infectious arthritis
- • Microcrystalline arthritis
About Gilles Boire
Gilles Boire is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative clinical studies. With a focus on delivering high-quality, evidence-based solutions, Gilles Boire collaborates with a diverse range of stakeholders, including healthcare professionals, research institutions, and regulatory bodies. The organization prioritizes patient safety and ethical standards while striving to accelerate the development of new therapies across various therapeutic areas. Through its rigorous methodologies and commitment to transparency, Gilles Boire aims to contribute significantly to the scientific community and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sherbrooke, Quebec, Canada
Patients applied
Trial Officials
Gilles Boire, MD, MSc
Principal Investigator
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials